[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 8,534
Citations 0
Clinical Trials Update
July 28, 2020

Novel Therapy Eradicates H pylori

JAMA. 2020;324(4):327. doi:10.1001/jama.2020.12592

Antimicrobial resistance to existing therapies has made Helicobacter pylori infection increasingly difficult to treat. In a phase 3 trial published in the Annals of Internal Medicine, a 3-drug combination of amoxicillin, omeprazole, and rifabutin in 1 capsule achieved high eradication rates of H pylori infection.

The study’s 455 treatment-naive adults with confirmed H pylori infection were randomly assigned to receive the novel study drug or high-dose amoxicillin and omeprazole dual therapy for 14 days.

Four weeks after the treatment ended, H pylori was eradicated in 83.8% of patients who received the rifabutin-based triple therapy compared with 57.7% in the omeprazole and amoxicillin group. The microbe’s resistance to clarithromycin or metronidazole did not affect eradication rates, and no rifabutin resistance was detected.